CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours

G. Pelosi, Filippo Fraggetta, Angelica Sonzogni, Nicola Fazio, Alessandra Cavallon, Giuseppe Viale

Research output: Contribution to journalArticlepeer-review


Although considered a specific marker for Ewing's sarcoma/peripheral neuroectodermal tumour, the MIC2 gene product (CD99) has been immunolocalised in a variety of human tumours. The present study evaluated immunohistochemically the prevalence of CD99 expression in a series of 68 neuroendocrine tumours of different gastrointestinal and pulmonary sites. We now report on membrane and/or granular cytoplasmic immunoreactivity in 25% of these tumours, independent of their anatomical sites. In lung neuroendocrine tumours, CD99 was preferentially confined to typical carcinoids (P=0.009). A statistically significant relationship was observed between the number of CD99 positive cells but not the immunostaining patterns and the presence of local invasion and/or distant metastases (P

Original languageEnglish
Pages (from-to)270-274
Number of pages5
JournalVirchows Archiv
Issue number3
Publication statusPublished - 2000


  • CD99 antigen
  • Cell-to-cell adhesion
  • Immunohistochemistry
  • Neuroendocrine tumours
  • Proliferative activity

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours'. Together they form a unique fingerprint.

Cite this